PTAB challenges

Proceedings overview

There is one active AIA trial proceeding on file for US patent 12274481. This Post-Grant Review (PGR) is currently pending institution, meaning the patent owner's claims have not yet been tested by the PTAB. Consequently, the patent is not yet hardened, nor have any claims been invalidated, leaving all claims of US12274481 available for assertion.

PGR2026-00022 — Paragon 28, Inc. v. Treace Medical Concepts Inc.

• Type: Post-Grant Review
• Filed: 2026-01-13
• Status: Pending – The PTAB is currently reviewing the petition to determine whether to institute a trial. The last modification was on 2026-05-15, which indicates ongoing administrative activity.
• Judge panel: Not yet publicly available, as the institution decision is pending.
• Petition grounds: The petition was filed by Paragon 28, Inc.. PGRs can challenge claims under 35 U.S.C. §§ 101, 102, 103, and 112 (except for best mode). Specific claims and prior art asserted are not yet publicly detailed in the provided structured data, nor are they typically available in a summary fashion before institution.
• Institution decision: Pending. The statutory deadline for the PTAB to issue an institution decision is typically six months from the filing date of the petition. For PGR2026-00022, filed on 2026-01-13, the institution decision is expected around July 13, 2026.
• Final Written Decision: Not yet issued, as the proceeding is pending institution.
• Settlement / termination: Not applicable, as the proceeding is active and pending institution.
• Appeal: Not applicable.
• Defensive value: This active PGR presents an opportunity to challenge the patentability of US12274481's claims. If instituted and successful, it could lead to claim cancellation, weakening the patent's enforceability. Conversely, if institution is denied or the patent owner prevails, the patent will gain strength.

Strategic summary

All claims of US12274481 are currently UNTESTED by the PTAB, as the sole proceeding, PGR2026-00022, is pending an institution decision. There are no claims that have been canceled or sustained by a PTAB Final Written Decision. The patent owner is Treace Medical Concepts Inc., and the petitioner is Paragon 28, Inc..

Regarding the estoppel landscape, since no trial has been instituted, no estoppel has yet attached under 35 U.S.C. § 325(e)(2). If PGR2026-00022 is instituted, the petitioner, Paragon 28, Inc., and its privies would be estopped from asserting invalidity grounds that were raised or reasonably could have been raised in the PGR against claims that result in a Final Written Decision. For a defendant currently facing assertion of this patent, all prior-art grounds remain available until an institution decision is made and, if instituted, until a Final Written Decision is issued.

There is no discernible pattern yet, as only one proceeding has been filed. The involvement of Paragon 28, Inc. as a petitioner suggests a potential competitive interest in challenging the patent.

Recommended next steps

For a defendant facing assertion of US12274481:

• Monitor the status of PGR2026-00022 closely. The institution decision is a critical upcoming milestone, expected around 2026-07-13.
• Review the PGR petition (once publicly available in the PTAB E2E system if not already) to understand the specific claims being challenged and the grounds asserted by Paragon 28, Inc. This information can help assess the strength of the challenges and inform your own invalidity analyses.
• Consider filing your own petition or joining the existing one, depending on your relationship with Paragon 28, Inc. and the specific legal strategy.## Proceedings overview
  There is one active AIA trial proceeding on file for US patent 12274481. This Post-Grant Review (PGR) is currently pending an institution decision. Consequently, the patent has not yet been challenged through a final written decision, nor have any claims been invalidated or sustained, leaving all claims of US12274481 available for assertion.

PGR2026-00022 — Paragon 28, Inc. v. Treace Medical Concepts Inc.

• Type: Post-Grant Review
• Filed: 2026-01-13
• Status: Pending – The Patent Trial and Appeal Board (PTAB) is currently reviewing the petition to determine whether to institute a trial. The last modification was on 2026-05-15, indicating ongoing administrative activity.
• Judge panel: Not yet publicly available, as the institution decision is pending.
• Petition grounds: Specific claims and prior art asserted are not publicly detailed in the provided structured data or general search results at this stage. However, PGRs can challenge claims under 35 U.S.C. §§ 101, 102, 103, and 112 (excluding the best mode requirement).
• Institution decision: Pending. The statutory deadline for the PTAB to issue an institution decision for a PGR is typically six months from the filing date of the petition. For PGR2026-00022, filed on 2026-01-13, the institution decision is expected around 2026-07-13.
• Final Written Decision: Not yet issued, as the proceeding is pending institution.
• Settlement / termination: Not applicable, as the proceeding is active and pending institution.
• Appeal: Not applicable.
• Defensive value: This active PGR presents a potential avenue for challenging the patentability of US12274481's claims. If the PTAB institutes the trial and ultimately issues a Final Written Decision unfavorable to the patent owner, it could lead to claim cancellation, weakening the patent's enforceability. Conversely, if institution is denied or the patent owner prevails, the patent will gain strength.

Strategic summary

All claims of US12274481 are currently UNTESTED by the PTAB. The sole proceeding, PGR2026-00022, is in the pre-institution phase, meaning no claims have been canceled or sustained by a PTAB Final Written Decision. The patent owner is Treace Medical Concepts Inc., and the petitioner is Paragon 28, Inc.

Regarding the estoppel landscape, since no trial has been instituted, no estoppel has yet attached under 35 U.S.C. § 325(e)(2). If PGR2026-00022 is instituted, the petitioner, Paragon 28, Inc., and its privies would be estopped from asserting invalidity grounds that were raised or reasonably could have been raised in the PGR against claims that are subject to a Final Written Decision. For a defendant currently facing assertion of this patent, all prior-art grounds for invalidity remain available until an institution decision is made and, if instituted, until a Final Written Decision is issued.

There is no discernible pattern yet, as only one proceeding has been filed. The involvement of Paragon 28, Inc. as a petitioner suggests a potential competitive or defensive interest in challenging the patent.

Recommended next steps

For a defendant facing assertion of US12274481:

• Monitor PGR2026-00022 closely: The institution decision for PGR2026-00022 is the next critical milestone and is expected around 2026-07-13.
• Review the PGR petition: Once publicly available in the USPTO's Patent Trial and Appeal Case Tracking System (P-TACTS), review the petition to understand the specific claims being challenged and the grounds asserted by Paragon 28, Inc. This information is crucial for assessing the strength of the challenges and can inform your own invalidity analyses.
• Evaluate intervention or parallel filing: Depending on your specific situation and strategic goals, consider whether intervening in the ongoing PGR or filing your own petition is appropriate.